VERTEX PHARMACEUTIC
VERTEX PHARMACEUTIC operates in Diversified Metals & Mining.
VERTEX PHARMACEUTIC (VX1) - Total Assets
Latest total assets as of September 2024: €22.24 Billion EUR
Based on the latest financial reports, VERTEX PHARMACEUTIC (VX1) holds total assets worth €22.24 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VERTEX PHARMACEUTIC - Total Assets Trend (2016–2023)
This chart illustrates how VERTEX PHARMACEUTIC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
VERTEX PHARMACEUTIC - Asset Composition Analysis
Current Asset Composition (December 2023)
VERTEX PHARMACEUTIC's total assets of €22.24 Billion consist of 62.2% current assets and 37.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 45.6% |
| Accounts Receivable | €1.56 Billion | 6.9% |
| Inventory | €738.80 Million | 3.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €839.90 Million | 3.7% |
| Goodwill | €1.09 Billion | 4.8% |
Asset Composition Trend (2016–2023)
This chart illustrates how VERTEX PHARMACEUTIC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VERTEX PHARMACEUTIC's current assets represent 62.2% of total assets in 2023, a decrease from 63.2% in 2016.
- Cash Position: Cash and equivalents constituted 45.6% of total assets in 2023, up from 40.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 10.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
VERTEX PHARMACEUTIC Competitors by Total Assets
Key competitors of VERTEX PHARMACEUTIC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
VERTEX PHARMACEUTIC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - VERTEX PHARMACEUTIC generates 0.43x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, VERTEX PHARMACEUTIC generates $ 15.92 in net profit.
VERTEX PHARMACEUTIC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.47 | 4.08 | 3.61 |
| Quick Ratio | 2.20 | 3.89 | 3.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.83 Billion | € 11.10 Billion | € 3.49 Billion |
VERTEX PHARMACEUTIC - Advanced Valuation Insights
This section examines the relationship between VERTEX PHARMACEUTIC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | €22.73 Billion |
| Market Capitalization | $4.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values VERTEX PHARMACEUTIC's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: VERTEX PHARMACEUTIC's assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for VERTEX PHARMACEUTIC (2016–2023)
The table below shows the annual total assets of VERTEX PHARMACEUTIC from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €22.73 Billion | +25.23% |
| 2022-12-31 | €18.15 Billion | +35.13% |
| 2021-12-31 | €13.43 Billion | +14.30% |
| 2020-12-31 | €11.75 Billion | +41.27% |
| 2019-12-31 | €8.32 Billion | +33.18% |
| 2018-12-31 | €6.25 Billion | +76.14% |
| 2017-12-31 | €3.55 Billion | +22.41% |
| 2016-12-31 | €2.90 Billion | -- |